This Biotech Stock 355% Breakout: Deep Track Bets Big
A biotech stock has surged 355%, catching the eye of every investor from day traders to pension funds. A prominent he...
Determine whether a 6-month or 12-month fund is right for you by assessing income stability, essential expenses, and personal risk appetite.
15,911 articlesA biotech stock has surged 355%, catching the eye of every investor from day traders to pension funds. A prominent he...
Axos Financial has delivered a notable 12-month gain, with a recent fund trim adding a twist to the story. This artic...
GTS Securities recently sold a large chunk of its XOVR exposure, shedding about 19.46 million shares worth roughly 35...
A major fund recently disclosed a sizable bet on The Andersons, flashing confidence in the agribusiness sector. This ...
A major hedge fund exit grabbed headlines as a fund controlled by William Oberndorf liquidated a sizable monday.com s...
A mid-sized industrial company delivered a dramatic rally, with Powell Industries stock surges pushing shares up dram...
A major fund stepped in with a bold $30 million wager on Floor & Decor after a sharp 30% decline. This article breaks...
Top U.S. homebuilders are backing Avila Real Estate Capital’s AREC Fund II, signaling a shift in housing finance as b...
A dividend-focused ETF can bring balance to a growth-heavy portfolio. This guide breaks down schwab u.s. dividend equ...
Fidelity’s zero-fee ETF has quietly tracked broad-market gains for years, delivering competitive returns with no expe...
The Columbia Research Enhanced Real Estate ETF (CRED) yields about 3.6% via pass-through REIT dividends. The fund’s i...
JPMorgan Chase is tightening its lending standards for private deals while a $33 billion private credit fund faces he...